Safety and Tolerability Study of Daily Dosing Rimegepant in Episodic Migraine Prevention
Safety and Tolerability Study of Daily Dosing Rimegepant in Episodic Migraine Prevention
NCT ID: NCT05207865 Phase: PHASE4 Status: COMPLETED Enrollment: 441 Completion: 2024-07-02
Conditions
Migraine, Episodic Migraine, Phonophobia, Photophobia
Interventions
Rimegepant
Summary
The purpose of this study is to further evaluate the long-term safety and tolerability of daily dosing of rimegepant for the prevention of episodic migraine.
Primary Outcome
Number of Participants With On-Treatment Adverse Events (AEs) (Frequency >=5%) According to Intensity